Table 2 Clinical characteristics at baseline and after three and six treatments with erenumab for the patients who presented with medication overuse (MOH) and non-medication overuse (nMOH) at baseline, before treatment initiation
From: A prospective real-world analysis of erenumab in refractory chronic migraine
Baseline | Month 3 | Month 6 | ||||
|---|---|---|---|---|---|---|
MOH | nMOH | MOH | nMOH | MOH | nMOH | |
Migraine days | 19.0 ± 0.9 | 19.9 ± 1.2 | 12.4 ± 1.2* | 14.7 ± 1.8 | 11.4 ± 1.3* | 13.3 ± 2.2# |
P = 0.2 | P = 0. 1 | P = 0. 1 | ||||
Headache Days | 23.2 ± 0.7 | 23.8 ± 0.8 | 15.3 ± 1.3* | 19.5 ± 1.6# | 15.7 ± 1.4* | 18.2 ± 2.0 |
P = 0.3 | P = 0.1 | P = 0. 1 | ||||
Crystal clear headache days | 4.6 ± 0.6 | 2.7 ± 0.6 | 9.4 ± 1.2* | 5.7 ± 1.4# | 8.2 ± 1.4* | 4.5 ± 1.5 |
P = 0.1 | P = 0.3 | P = 0. 1 | ||||
Days consumed abortives | 17.9 ± 0.7 | 4.0 ± 0.4 | 10.3 ± 1.0* | 4.4 ± 0.6 | 9.7 ± 1.1* | 3.8 ± 0.7 |
P < 0.001 | P = 0.1 | P = 0. 001 | ||||
HIT-6 | 66.7 ± 1.0 | 66.7 ± 1.0 | 58.3 ± 1.3* | 60.2 ± 2.2# | 53.4 ± 3.1* | 62.1 ± 4.3 |
P = 0.8 | P = 0.2 | P = 0. 4 | ||||